Unavailable
Unavailable
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 2/25/2022 | $6.00 | Buy | Maxim Group |
8-K - NEXGEL, INC. (0001468929) (Filer)
10-Q - NEXGEL, INC. (0001468929) (Filer)
424B5 - NEXGEL, INC. (0001468929) (Filer)
4 - NEXGEL, INC. (0001468929) (Issuer)
4 - NEXGEL, INC. (0001468929) (Issuer)
4 - NEXGEL, INC. (0001468929) (Issuer)
Management will host a conference call at 4:30 P.M. ET on the same day LANGHORNE, Pa., Nov. 11, 2024 (GLOBE NEWSWIRE) -- NEXGEL, Inc. ("NEXGEL" or the "Company") (NASDAQ: "NXGL"), a leading provider of ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, today announced it will report its financial results for the third quarter 2024, after the market close on November 13, 2024. Following the release of its financial results, the Company will host a conference call at 4:30 P.M. ET on the same day. Third Quarter 2024 Financial Results Conference CallDate: November 13, 2024Time: 4:30 P.M. ETLive Call: 1-800-225-9448 (U.S. Toll Free) or 1-203-518-9708
LANGHORNE, Pa., Oct. 10, 2024 (GLOBE NEWSWIRE) -- NEXGEL, Inc. ("NEXGEL" or the "Company") (NASDAQ: "NXGL"), a leading provider of medical and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogels for healthcare and consumer applications, today announced preliminary, unaudited expected record revenue for the third quarter 2024 of approximately $2.85 million, an increase of approximately 133% year-over-year and approximately 98% quarter-over-quarter, respectively, as well as an increase of approximately 30% over the Company's previously issued July third quarter revenue guidance of $2.20 million. "We are pleased to announce yet another record revenue quarter,
Management will host a conference call at 4:30 P.M. ET on the same day LANGHORNE, Pa., Aug. 12, 2024 (GLOBE NEWSWIRE) -- NEXGEL, Inc. ("NEXGEL" or the "Company") (NASDAQ: "NXGL"), a leading provider of medical and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogels for healthcare and consumer applications, today announced it will report its financial results for the second quarter 2024, after the market closes on August 14, 2024. Following the release of its financial results, the Company will host a conference call at 4:30 P.M. ET on the same day. Second Quarter 2024 Financial Results Conference CallDate: August 14, 2024Time: 4:30 P.M. ETLive Call: + 1-8
4 - NEXGEL, INC. (0001468929) (Issuer)
4 - NEXGEL, INC. (0001468929) (Issuer)
3 - NEXGEL, INC. (0001468929) (Issuer)
LANGHORNE, Pa., Jan. 02, 2025 (GLOBE NEWSWIRE) -- NEXGEL, Inc. ("NEXGEL" or the "Company") (NASDAQ: "NXGL"), a leading provider of medical and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogels for healthcare and consumer applications, today announced the appointment of Joseph F. McGuire as Chief Financial Officer, effective January 1, 2025. Adam E. Drapczuk III, current Chief Financial Officer, will remain with the Company as a consultant. Adam Levy, Chief Executive Officer, stated, "As our business continues to experience high growth, it is imperative we consistently acquire talented and experienced professionals to join our team particularly in operati
LANGHORNE, Pa., Nov. 21, 2024 (GLOBE NEWSWIRE) -- NEXGEL, Inc. ("NEXGEL" or the "Company") (NASDAQ: "NXGL"), a leading provider of medical and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogels for healthcare and consumer applications, today announced that Adam Levy, Chief Executive Officer, will present at the iAccess Alpha Virtual Best Ideas Winter Conference 2024 on December 10 and 11, 2024. iAccess Alpha Virtual Conference Details:Date: December 10-11, 2024Presentation Day and Time: Tuesday, December 10th at 10:30 a.m. ETWebcast: https://www.webcaster4.com/Webcast/Page/3074/51540 To schedule a one-on-one investor meeting with Mr. Levy, please contact
Quarterly revenue growth driven by a sequential increase of 99% in branded consumer products and 103% in contract manufacturing Gross profit margin for the quarter was 43.6% compared to 28.2% in Q3 of 2023 and 28.5% in Q2 of 2024 LANGHORNE, Pa., Nov. 13, 2024 (GLOBE NEWSWIRE) -- NEXGEL, Inc. ("NEXGEL" or the "Company") (NASDAQ: "NXGL"), a leading provider of ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, today announced record third quarter revenue of $2.94 million, an increase of 141% year-over-year and 104% sequentially. Third Quarter 2024 Financial Highlights: Net Revenue was $2.94 million, compared to $1.22 million in Q3 2023 and $1.44
Maxim Group initiated coverage of NexGel with a rating of Buy and set a new price target of $6.00
LANGHORNE, Pa., Jan. 02, 2025 (GLOBE NEWSWIRE) -- NEXGEL, Inc. ("NEXGEL" or the "Company") (NASDAQ: "NXGL"), a leading provider of medical and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogels for healthcare and consumer applications, today announced the appointment of Joseph F. McGuire as Chief Financial Officer, effective January 1, 2025. Adam E. Drapczuk III, current Chief Financial Officer, will remain with the Company as a consultant. Adam Levy, Chief Executive Officer, stated, "As our business continues to experience high growth, it is imperative we consistently acquire talented and experienced professionals to join our team particularly in operati
LANGHORNE, Pa., Oct. 04, 2024 (GLOBE NEWSWIRE) -- NEXGEL, Inc. ("NEXGEL" or the "Company") (NASDAQ: "NXGL"), a leading provider of medical and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogels for healthcare and consumer applications, today announced the appointment of Kip Crecca to its Scientific Advisory Board. "We are thrilled to appoint Kip to our Scientific Advisory Board. He adds to our team a wealth of knowledge and experience as a top medical device sales professional," said Adam Levy, NEXGEL's CEO. "Mr. Crecca will be invaluable to the Company as we advance our medical device and healthcare programs. He is an important addition to our group of e
LANGHORNE, Pa., Jan. 17, 2023 /PRNewswire/ -- NEXGEL, Inc. (NASDAQ:NXGL, NXGLW))), ("NEXGEL" or the "Company"), a leading provider of ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, announced today the appointment of Scott Henry, CFA as a new independent director to the Company's Board of Directors (the "Board"), effective immediately. Mr. Henry will also serve as a member of the Board's Audit Committee. "Scott brings a wealth of financial and operational experience to NEXGEL, making him an ideal addition to our Board and Audit Committee," said Adam Levy, Chief Executive Officer of NEXGEL. "Additionally, his vast network within the investment comm